Lipella Pharmaceuticals Inc. (LIPO)
LIPO is quoted over the counter, not listed on an exchange. Lipella Pharmaceuticals Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | LIPO, quoted over the counter |
| SEC CIK | 0001347242 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Pittsburgh, PA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2025-11-14 |
| Cash and burn | $1.9M cash; operating cash flow -$1.2M a quarter. | Report 2025-09-30 |
| Shares outstanding | 4,620,837 (2025-11-13); 1,208,919 a year earlier. the newest SEC cover-page count is from 2025-11-13; shares issued since then are not in these figures. | Cover page 2025-11-13 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2024-11-08 | Source 2024-11-08 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-10-06 |
| Auditor | Urish Popeck & Company, LLC, Pittsburgh, Pennsylvania, United States | PCAOB Form AP 2025-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2025 2025-09-30 | $0 | -$1.3M | -$926K | $1.9M | $0 | $390K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $87K | -$1.3M | -$1.4M | $2.8M | $0 | $470K | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | $129K | -$1.3M | -$1.4M | $4.2M | $0 | $520K | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $174K | -$1.4M | -$990K | $2.2M | $0 | $536K | 10-K 2025-03-28 |
| Q3 2024 2024-09-30 | $80K | -$1.4M | -$653K | $1.4M | $0 | $484K | 10-Q 2025-11-14 |
| Q2 2024 2024-06-30 | $136K | -$938K | -$919K | $1.2M | $0 | $507K | 10-Q 2025-08-14 |
| Q1 2024 2024-03-31 | $146K | -$1.2M | -$1.4M | $2.1M | No debt tags | $477K | 10-Q 2025-05-14 |
| Q4 2023 2023-12-31 | $121K | -$689K | -$728K | $3.3M | $0 | $450K | 10-K 2025-03-28 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-04-04 |
| Latest annual report | 10-K | 2025-03-28 |
| Latest quarterly / interim | 10-Q | 2025-11-14 |
| Latest current report | 8-K | 2026-07-15 |
| Latest proxy | PRE 14A | 2025-06-10 |
Source: SEC EDGAR submissions feed, 225 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier